Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey.
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Support Care Cancer. 2023 Mar 1;31(3):194. doi: 10.1007/s00520-023-07652-3.
This study aimed to evaluate clinical pharmacist's contribution to the pneumococcal vaccination rate by providing education to cancer patients in hospital settings.
This study was conducted in 2 tertiary-care hospitals' medical oncology outpatient clinics. Patients over 18 years of age and diagnosed with cancer for less than 2 years, in remission stage, and have not previously received the pneumococcal vaccine were included. Patients were randomized to intervention and control groups. The intervention group was provided vaccination education and recommended to receive the PCV13 vaccine. The control group received routine care. Patients' knowledge about pneumonia/pneumococcal vaccine, Vaccine Attitude Examination Scale (VAX) score, and vaccination rates were evaluated at baseline and 3 months after the education.
A total of 235 patients (intervention: 117, control: 118) were included. The mean age ± SD was 57.86 ± 11.88 years in the control and 60.68 ± 11.18 years in the intervention groups. The numbers of correct answers about pneumonia/pneumococcal vaccine (p = 0.482) and VAX scores (p = 0.244) of the groups were similar at baseline. After the intervention, the median (IQR) number of correct answers in intervention group [10(3)] was higher than control group [8(4)] (p < 0.001). After the education, the total VAX score (mean ± SD) was less in intervention group (33.09 ± 7.018) than the control group (36.07 ± 6.548) (p = 0.007). Three months after the education, 20.2% of the patients in the intervention and 6.1% in the control groups were vaccinated with pneumococcal vaccine (p = 0.003).
The pneumococcal vaccination rate in cancer patients has increased significantly by the education provided by a clinical pharmacist in hospital settings.
本研究旨在通过在医院环境中为癌症患者提供教育,评估临床药师对肺炎球菌疫苗接种率的贡献。
本研究在 2 家三级保健医院的肿瘤内科门诊进行。纳入年龄大于 18 岁、确诊癌症时间少于 2 年、处于缓解期且既往未接种过肺炎球菌疫苗的患者。患者被随机分为干预组和对照组。干预组接受疫苗接种教育并建议接种 PCV13 疫苗。对照组接受常规护理。在基线和教育后 3 个月评估患者对肺炎/肺炎球菌疫苗的知识、疫苗态度量表(VAX)评分和接种率。
共纳入 235 例患者(干预组 117 例,对照组 118 例)。对照组的平均年龄(±标准差)为 57.86 ± 11.88 岁,干预组为 60.68 ± 11.18 岁。两组对肺炎/肺炎球菌疫苗的正确答案数量(p=0.482)和 VAX 评分(p=0.244)在基线时相似。干预后,干预组中位数(IQR)正确答案数[10(3)]高于对照组[8(4)](p<0.001)。教育后,干预组的总 VAX 评分(均值±标准差)[33.09 ± 7.018]低于对照组[36.07 ± 6.548](p=0.007)。教育后 3 个月,干预组 20.2%的患者和对照组 6.1%的患者接种了肺炎球菌疫苗(p=0.003)。
通过临床药师在医院环境中提供教育,癌症患者的肺炎球菌疫苗接种率显著提高。